Alkermes Raises Offer To Acquire Avadel In Deal Worth Up To $22.50 Per Share

Alkermes agreed to acquire Avadel for up to $22.50 per share—$21.00 cash plus a $1.50 contingent value right payable if the FDA grants final approval of LUMRYZ for idiopathic hypersomnia by end-2028—valuing Avadel at about $2.37 billion with the deal expected to close in Q1 2026. The companies amended their Oct. 22 definitive agreement on Nov. 18 after Avadel, which had received an unsolicited proposal from H. Lundbeck A/S that it initially deemed a potential superior bid, concluded following Alkermes’ improved offer that the Lundbeck proposal no longer qualifies as a superior proposal. J.P. Morgan is Alkermes’ exclusive financial adviser; Avadel shares ticked up roughly 1.6% pre-market while Alkermes was modestly lower, and the transaction’s economics hinge on the regulatory approval risk around LUMRYZ.

Analysis

Alkermes agreed to acquire Avadel for up to $22.50 per share — $21.00 in cash plus a non-transferable $1.50 contingent value right (CVR) payable if the FDA grants final approval of LUMRYZ for idiopathic hypersomnia in adults by the end of 2028, valuing Avadel at about $2.37 billion and with an expected close in Q1 2026. Avadel shares ticked up 1.57% in pre-market trading after a $22.94 close, while Alkermes shares were modestly lower at $29.26 (down 0.24%), reflecting mixed market sentiment around deal economics and execution risk.

The companies executed an amendment on Nov. 18 to the Oct. 22 definitive agreement after Avadel received an unsolicited proposal from H. Lundbeck A/S on Nov. 14; Avadel's board initially treated Lundbeck as a potential superior proposal but, following Alkermes’ increased offer, concluded Lundbeck no longer qualified. J.P. Morgan is Alkermes' exclusive financial adviser and legal counsel for both sides has been engaged, indicating standard M&A advisory and governance processes are in place.

The principal value driver and risk is regulatory: the $1.50 CVR is contingent on FDA approval of LUMRYZ by end-2028, creating binary upside for Avadel holders and leaving a prolonged window for regulatory, shareholder and competing-bid risk through the expected Q1 2026 close; the non-transferable nature of the CVR limits secondary-market monetization of that upside. For Alkermes, the deal expands its pipeline into sleep disorders but introduces approval, integration and potential financing considerations that could affect near-term shareholder returns.

Key Decisions for Investors

• Avadel shareholders should compare the certain $21 cash component to the $22.94 last close and consider taking the cash if they prefer liquidity given the CVR's approval contingency and non-transferability
• Alkermes investors should monitor deal financing disclosures, potential dilution and integration risk since the transaction's value rests on a regulatory milestone and initial market reaction was mildly negative
• Event-driven investors should track FDA progress on LUMRYZ, any resurgence of rival bids (notably H. Lundbeck), and material amendments during the long close window to evaluate arbitrage or hedging opportunities